Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBT (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EBT for 5 consecutive years, with -$14.4 million as the latest value for Q4 2025.

  • For Q4 2025, EBT rose 28.96% year-over-year to -$14.4 million; the TTM value through Dec 2025 reached -$55.3 million, up 33.94%, while the annual FY2025 figure was -$54.7 million, 34.72% up from the prior year.
  • EBT hit -$14.4 million in Q4 2025 for Kezar Life Sciences, down from -$10.7 million in the prior quarter.
  • Across five years, EBT topped out at -$10.7 million in Q3 2025 and bottomed at -$32.3 million in Q4 2023.
  • Average EBT over 5 years is -$18.2 million, with a median of -$17.2 million recorded in 2022.
  • Year-over-year, EBT crashed 77.44% in 2023 and then soared 47.38% in 2025.
  • Kezar Life Sciences' EBT stood at -$14.2 million in 2021, then dropped by 27.93% to -$18.2 million in 2022, then plummeted by 77.44% to -$32.3 million in 2023, then soared by 37.33% to -$20.2 million in 2024, then rose by 28.96% to -$14.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$14.4 million, -$10.7 million, and -$13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.